Oncaspar 3,750 unit/5 ML vial 5ML
Ended Awarded
- Contract number
- SPE2DR26FMDT8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,351
Award facts
- Contract value 100% obligated
- $27,351.45 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $27,351.45 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. The delivery order, issued on October 27, 2025, procures 3,750 units of Oncaspar 5 mL vials, an oncology pharmaceutical product, with completion scheduled for November 18, 2025. This award was made without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. No subcontractors were identified on this award.
This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded on November 13, 2025, carries a $499.9 billion ceiling value and extends through December 31, 2036, comprising a 30-month base period with three 30-month option periods. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to provide pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across multiple delivery orders and its comprehensive product portfolio position the company as a critical pharmaceutical supplier within the federal military medical system's supply chain.
Quick answers
Who was awarded contract SPE2DR26FMDT8?
SPE2DR26FMDT8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DR26FMDT8 worth?
The government has obligated $27,351 on SPE2DR26FMDT8.
Is contract SPE2DR26FMDT8 an order under another contract?
Yes. SPE2DR26FMDT8 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDT8 competed?
The extent of competition for SPE2DR26FMDT8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award